Researchers at McMaster University have invented a stable, affordable way to store fragile vaccines for weeks at a time at temperatures up to 40C, opening the way for life-saving anti-viral vaccines to reach remote and impoverished regions of the world.
The new method combines the active ingredients in existing vaccines with a sugary gel, where they remain viable for eight weeks or more, even at elevated temperatures.
The method creates light, durable, and compact doses that would be ideal for shipping Ebola vaccine, for example, to affected regions of Africa, the researchers say. The process adds only marginal cost to preparing a vaccine and eliminates almost all the cost of transporting it – which can account for 80 per cent of the total cost of inoculation.
Combining the vaccines and the sugars – pullulan and trehalose – is almost as simple as stirring cream and sugar into coffee, the researchers say. The storage technology was created by chemical engineers at McMaster, who had already demonstrated its effectiveness in other applications, such as an edible coating that can prolong the shelf life of fruits and vegetables.
To apply the technology to vaccines, the engineers collaborated with health sciences colleagues across campus who specialize in virology and immunology. Their work is published today in the journal Scientific Reports and also appeared on the front page of the Globe and Mail newspaper.
“This, to us, is the ultimate application of this technology,” said the paper’s lead author Vincent Leung, an assistant professor of Chemical Engineering. “To imagine that something we worked on in the lab could one day be used to save people’s lives is very exciting.”
The invention is significant because it can replace the cumbersome “cold chain” – constant storage at temperatures between 2C and 8C – which is currently necessary to keep anti-viral vaccines viable. Maintaining the cold chain is a significant barrier to inoculating people in remote or poor regions of the world, where the infrastructure to refrigerate and transport vaccines smoothly may not be available.
“You can spend all kinds of money developing a vaccine, but if it is deactivated by high temperature an hour before you can give it to someone, it doesn’t matter,” says co-author Ali Ashkar, a professor of Pathology and Molecular Medicine specializing in immunology.
The cold-chain challenge is so great, the researchers say, that in some regions, vaccines must be transported by camels bearing solar-powered mini-refrigerators. There are some populations that never receive vaccines.
“If you can’t get vaccines to the places where people need them, there’s no point in having them,” says co-author Matthew Miller, an assistant professor in the Department of Biochemistry and Biomedical Sciences whose laboratory specializes viral pathogens.
Not being able to get vaccines to isolated areas makes it impossible to eradicate deadly viruses. Unchecked, such viruses can devastate local populations and reach exposed pockets in more populated countries where religious, cultural or other concerns have diminished the proportion of vaccinated individuals. Such a scenario has recently been playing out in in a measles outbreak in the US northwest and Vancouver, BC.
The new vaccine-storage method suspends the active components of a vaccine in a tiny one-dose container filled with a sugar-gel combination that dries to seal in the vaccine. Later, clinicians reconstitute the vaccine with water and administer it to patients as they ordinarily would.
“Often, complex problems have simple solutions. It just takes the right team,” says Miller. “The best research comes from merging fields, when you do something with someone else that you couldn’t do alone.”
The researchers have proven the method to be viable using two sample vaccines – influenza virus and herpes simplex virus – to inoculate and test mice by exposing them to the viruses because the immune response of mice is similar to that of humans. The materials in the storage medium are already approved by the US Food and Drug Administration, simplifying the path to commercialization.
“All the pieces are ready to go,” says co-author Carlos Filipe, chair of Chemical Engineering at McMaster. “It’s actually quite simple compared to the technology required to create a vaccine itself.”
The researchers are working with a commercial partner to get the technology to market.
Learn more: McMaster researchers invent a way to get life-saving vaccines to previously inaccessible parts of the world
The Latest on: Vaccine storage
[google_news title=”” keyword=”vaccine storage” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vaccine storage
- The AstraZeneca vaccine – should you be worried?on May 11, 2024 at 1:00 am
Earlier this week, the European Commission announced that the Covid-19 vaccine, developed as part of a collaboration between the British pharma company AstraZeneca and University of Oxford, is no ...
- Leveraging vaccine potential to end meningitis scourgeon May 10, 2024 at 8:09 pm
This includes improving vaccine supply chains, enhancing cold chain storage facilities, and increasing public awareness about the importance of vaccination. Despite the MenFive programme, Nigeria ...
- These Stocks Are Moving the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, SoundHound, JFrog, Gen Digital, and Moreon May 10, 2024 at 9:46 am
Stocks traded mostly higher Friday and the Dow Jones Industrial Average was up for an eighth-straight day with equities rallying on strong earnings and the belief that the Federal Reserve might be ...
- Whooping cough: Vaccine expert 'very worried' by whooping cough deathson May 10, 2024 at 5:23 am
A leading vaccine expert says he is "very worried" by the large increase in whooping cough cases which have led to the deaths of five babies in England this year. Professor Sir Andrew Pollard, head of ...
- AstraZeneca Withdraws Covid Vaccine After 3 Billion Shots Administered — But Why?on May 8, 2024 at 7:48 am
AstraZeneca discontinues widely used COVID-19 vaccine due to surplus and emerging variants, citing declining demand and emerging alternatives amid rare side effects reports.
- AstraZeneca withdraws Covid-19 vaccineon May 8, 2024 at 5:55 am
AstraZeneca Plc pulled its Covid-19 vaccine from the market due to lack of demand for a shot that initially raised hopes it would play a key role in protecting the world against the virus.
- At request of AstraZeneca, Europe withdraws marketing authorization of COVID vaccine Vaxzevriaon May 8, 2024 at 4:33 am
the company abandoned its efforts to gain approval of the shot in the U.S. The vaccine was the preferred shot in many of the world’s poorer nations because it was cheaper to manufacture and to ...
- AstraZeneca Withdraws COVID-19 Vaccine Globally; Faces Legal Challenges Over Side Effectson May 8, 2024 at 1:50 am
AstraZeneca, the pharmaceutical giant, has declared a worldwide retraction of their COVID-19 vaccine due to legal hiccups relating to its side-effects.
- Ukraine Upgrades Vaccine Storage Equipment Thanks To World Bank Projecton May 6, 2024 at 9:58 pm
As part of the project Emergency response to COVID-19 and vaccination in Ukraine, financed by the World Bank, a systematic replacement of vaccine sto ...
- How safe is AstraZeneca Covid vaccine & why there is no need to panic — some key questions answeredon May 1, 2024 at 9:32 am
UK court against biopharma company over claims that its Covid vaccine caused death and injury in several cases.
via Bing News